Retrophin, the biotech venture of former hedge fund manager Martin Shkreli, startled investors Friday morning when it revealed that elevated levels of liver enzymes briefly derailed a study of its rare disease candidate, sending the company’s shares down more than 8%.

…read more

Source: Retrophin slips on liver woes in rare disease drug’s first trial


0 No comments